Core Viewpoint - The approval of the supplemental new drug application for ADASUVE® by the FDA marks a significant regulatory milestone for the company, facilitating the commercial production of the product in the U.S. [1][2] Group 1: FDA Approval and Production - The FDA approved the supplemental new drug application for ADASUVE® on December 29, 2025, allowing the commercial production facility to be relocated from Mountain View, California, to Fremont, California [1] - The application was originally submitted to the FDA on August 29, 2025, by the previous owner, and the company's wholly-owned subsidiary, Nova Pneuma Incorporated (NPI), acquired the relevant assets in December 2025 [1] Group 2: Strategic Implications - The FDA approval signifies the completion of regulatory requirements associated with the company's first pharmaceutical facility acquisition in the U.S. [2] - The board believes this approval supports the company's strategy to expand its innovative drug delivery technology portfolio based on the Staccato® platform, which has the potential for application in various therapeutic indications [2]
李氏大药厂(00950.HK)：FDA批准《ADASUVE®》的补充新药上市申请